Approval · Notice of Compliance 18900 · 2017
INVOKAMET: Notice of Compliance 18900
Issued January 20, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18900
- Date
- January 20, 2017
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph to include increased risk of bone fractures with the use of canaglifozin in response to an advisory letter
Products in this notice
Medicinal ingredients
- METFORMIN HYDROCHLORIDE 500 MG per MG
- CANAGLIFLOZIN 50 MG per MG
- METFORMIN HYDROCHLORIDE 850 MG per MG
- METFORMIN HYDROCHLORIDE 50 MG per MG
- CANAGLIFLOZIN 1,000 MG per MG
- METFORMIN HYDROCHLORIDE 150 MG per MG
- CANAGLIFLOZIN 500 MG per MG
- CANAGLIFLOZIN 850 MG per MG